Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/978-1-4613-1713-5_5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Synthesis and preliminary evaluation of Tc-Hynic-fragments [F(ab') and F(ab')] of Rituximab as radioimmunoscintigraphic agents for patients with Non-Hodgkin's lymphoma.
Appl Radiat Isot
November 2019
Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, 400 085, India; Homi Bhabha National Institute, Anushakti Nagar, Mumbai, 400 094, India.
This study was to evaluate the potential of Tc-Hynic-fragments of Rituximab as radioimmunoscintigraphic agents for diagnosis of patients with Non-Hodgkin's Lymphoma (NHL). Rituximab was digested with immobilized pepsin and papain to yield F(ab')-Rituximab and F(ab')-Rituximab fragments respectively. Purified fragments were characterized by SE-HPLC and SDS-PAGE and subsequently radiolabeled with technetium-99m using Hynic as bifunctional chelator.
View Article and Find Full Text PDF[Radioimmunoimaging of lymphoma in mice with a two-step pretargeting strategy using biotinyled CD45 monoclonal antibody and (188)Re-avidin].
Nan Fang Yi Ke Da Xue Xue Bao
August 2015
Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. E-mail:
Objective: To establish a two-step pretargeting approach to lymphoma radioimmunoimaging in mice using biotinynaled CD45 monoclonal antibody (McAb) and (188)Re-avidin in a tumor-bearing mouse model.
Methods: Six Nod-Scid mice bearing lymphoma cell xenograft were randomized to receive either an intravenous injection of 50 µg/200 µL biotinyled CD45 McAb followed 24 h later by an intraperitoneal injection of 3.7 MBq (50 µg/100 µL) (188)Re-avidin (two-step pretargeting group), or a single intravenous injection of 3.
INTRODUCTION The availability of monoclonal antibodies in Cuba has facilitated development and application of innovative techniques (immunoscintigraphy and radioimmunotherapy) for cancer diagnosis and treatment. Objective Review immunoscintigraphy and radioimmunotherapy techniques and analyze their use in Cuba, based on the published literature. In this context, we describe the experience of Havana's Clinical Research Center with labeled monoclonal antibodies for cancer diagnosis and treatment during the period 1993-2013.
View Article and Find Full Text PDF⁹⁹mTc carbonyl DTPA-rituximab: preparation and preliminary bioevaluation.
Appl Radiat Isot
April 2014
Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India. Electronic address:
The anti CD20 antibody Rituximab was conjugated with para isothiocyanato benzyl diethylene triamine penta acetic acid (p-NCS-Bz-DTPA) and subsequent radiolabeling with (99m)Tc was carried out via the (99m)Tc carbonyl synthon. The (99m)Tc labeled antibody conjugate exhibited >95% radiochemical purity after purification and retained good in vitro stability when studied up to 24h at room temperature. In vitro cell binding studies carried out in Raji cells expressing CD20 antigen validated the biological efficacy of the preparation.
View Article and Find Full Text PDF[Radiolabeled antibodies for cancer treatment].
Med Sci (Paris)
December 2009
Centre de recherche en cancérologie de Nantes-Angers, Université de Nantes, Inserm, U892, Institut de biologie, 9, quai Moncousu, 44000 Nantes, France.
Article Synopsis
- The first successful radio-immunotherapy (RIT) treatment was performed in 1951, with ongoing research focusing on applying it beyond non-Hodgkin's lymphoma to other cancer types.
- Solid tumors pose a greater challenge due to their radioresistance, but RIT might benefit cases with small lesions or minimal residual disease.
- Current advancements include pretargeting strategies to improve tumor targeting and the exploration of new radionuclides like Lutetium-177 and copper-67, which could enhance RIT's effectiveness when combined with other treatment methods.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!